Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico

Favipiravir was initially developed as an antiviral drug against influenza and is currently used in clinical trials against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (COVID-19). This agent is presumably involved in RNA chain termination during influenza virus replication...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Microorganisms
मुख्य लेखकों: Sada, Mitsuru, Saraya, Takeshi, Ishii, Haruyuki, Okayama, Kaori, Hayashi, Yuriko, Tsugawa, Takeshi, Nishina, Atsuyoshi, Murakami, Koichi, Kuroda, Makoto, Ryo, Akihide, Kimura, Hirokazu
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: MDPI 2020
विषय:
Communication
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7589801/
https://ncbi.nlm.nih.gov/pubmed/33092045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/microorganisms8101610
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन